Clearside Biomedical, Inc. (CLSDQ)
OTCMKTS · Delayed Price · Currency is USD
0.2490
0.00 (0.00%)
Inactive · Last trade price on Jul 13, 2026
Clearside Biomedical Employees
Clearside Biomedical had 32 employees as of December 31, 2024. The number of employees increased by 2 or 6.67% compared to the previous year.
Employees
32
Change (1Y)
2
Growth (1Y)
6.67%
Revenue / Employee
$104,031
Profits / Employee
-$812,375
Market Cap
18.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 32 | 2 | 6.67% |
| Dec 31, 2023 | 30 | -6 | -16.67% |
| Dec 31, 2022 | 36 | 2 | 5.88% |
| Dec 31, 2021 | 34 | 1 | 3.03% |
| Dec 31, 2020 | 33 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Clearside Biomedical News
- 8 days ago - Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor - Business Wire
- 8 months ago - Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - GlobeNewsWire
- 8 months ago - Clearside Biomedical Quarterly report: Q3 2025 - Filings
- 11 months ago - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - GlobeNewsWire
- 1 year ago - Clearside Biomedical Quarterly report: Q2 2025 - Filings
- 1 year ago - Clearside Biomedical Proxy statement: Proxy Filing - Filings
- 1 year ago - Clearside Biomedical Proxy statement: Proxy Filing - Filings
- 1 year ago - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - GlobeNewsWire